Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Newly Diagnosed Ph+ CML-CP
NCT01274351Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started Jan 2011; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01274351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01274351.